Full Name
Ruth O'Regan, MD
Speaker Bio
Dr. Ruth O’Regan, M.D. is Chair of Medicine at the University of Rochester and Physician-in-Chief of Strong Memorial Hospital. A leading breast cancer researcher, she has held major leadership roles at the University of Wisconsin, Emory University, and the Big Ten Cancer Research Consortium. Her work focuses on therapy resistance, especially in triple-negative breast cancer.
Speaking At
GS1-07 - Adjuvant palbociclib in HR+/HER2- early breast cancer: Final protocol-planned analysis results from 5,761 patients in the randomized phase III PALLAS trial
GS2-02 - Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/ HER2- advanced / metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy
GS2-05 - Randomized comparisons of adjuvant exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS vs tamoxifen in premenopausal women with HR+ early breast cancer: update of the TEXT and SOFT trials
GS3-10 - Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDKz, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
GS3-09A - Circulating Tumor Cells-driven choice of first line therapy for HR+ HER2- metastatic breast cancer
GS1-06 - Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial
GS1-09 - Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
GS3-01A - EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting
RF01-01 - SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)
RF01-01 SERENA-3 - A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer (China)
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy (China)
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study (China)
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification (China)
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer (China)
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC (China)
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE) (China)
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
GS2-02 - Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/ HER2- advanced / metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy
GS2-05 - Randomized comparisons of adjuvant exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS vs tamoxifen in premenopausal women with HR+ early breast cancer: update of the TEXT and SOFT trials
GS3-10 - Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDKz, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer
GS3-09A - Circulating Tumor Cells-driven choice of first line therapy for HR+ HER2- metastatic breast cancer
GS1-06 - Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial
GS1-09 - Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
GS3-01A - EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting
RF01-01 - SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE)
RF01-01 SERENA-3 - A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2-negative primary cancer (China)
RF01-02 - A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy (China)
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study (China)
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification (China)
RF01-06 - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer (China)
RF01-07 - The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC (China)
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE) (China)
GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25).
GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.
GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database.
